These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37109622)

  • 1. Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema.
    Kusuhara S; Kishimoto-Kishi M; Matsumiya W; Miki A; Imai H; Nakamura M
    Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109622
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment Effects of Switching to Faricimab in Eyes with Diabetic Macular Edema Refractory to Aflibercept.
    Tatsumi T; Kaiho T; Iwase T; Miura G; Shimizu D; Niizawa T; Ozawa Y; Arai M; Oshitari T; Takatsuna Y; Baba T
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792915
    [No Abstract]   [Full Text] [Related]  

  • 3. Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept.
    Ohara H; Harada Y; Hiyama T; Sadahide A; Minamoto A; Kiuchi Y
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374329
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema.
    Takamura Y; Yamada Y; Morioka M; Gozawa M; Matsumura T; Inatani M
    Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):31. PubMed ID: 37856112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema.
    Byeon SH; Kwon YA; Oh HS; Kim M; Kwon OW
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):387-94. PubMed ID: 17803438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME).
    Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Guthux F; Blin P; Grelaud A
    Ophthalmic Res; 2021; 64(4):577-586. PubMed ID: 32932257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
    Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections.
    Chang YC; Huang YT; Hsu AY; Meng PP; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Lin JM; Chen WL; Tsai YY
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984630
    [No Abstract]   [Full Text] [Related]  

  • 12. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
    Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
    Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFECT OF BASELINE CENTRAL RETINAL THICKNESS ON THE RESULTS OF TREATMENT OF DIABETIC MACULAR EDEMA WITH AFLIBERCEPT: REAL-LIFE EVIDENCE IN THE CZECH REPUBLIC.
    Němčanský J; Stepanov A; Veith M; Koubek M; Kopecký A; Němčanská S; Beran D; Studnička J
    Cesk Slov Oftalmol; 2022; 78(2):64-70. PubMed ID: 35477246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Term Clinical Outcomes of Patients with Diabetic Macular Edema Following a Therapy Switch to Faricimab.
    Wolfrum P; Böhm EW; Lorenz K; Stoffelns B; Pfeiffer N; Korb CA
    J Clin Med; 2024 Aug; 13(15):. PubMed ID: 39124774
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
    Savur F; Kaldırım H; Atalay K; Korkmaz Ş
    Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
    Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Long-term Outcomes in Diabetic Macular Edema Patients: With or without Additional Injection Following Ranibizumab Loading.
    Yoon K; Kim ES; Yu SY; Kim K
    Korean J Ophthalmol; 2022 Oct; 36(5):398-406. PubMed ID: 35989066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.